Nebenwirkungen · Adasuve
ADASUVE 4.5 mg inhalation powder, pre-dispensed · Abschnitt 4.8 · PDF-Seite 8
HOS-215507 · Präparat HOS-155450
In short-term (24-hour), placebo-controlled trials in patients with agitation associated with schizophrenia or bipolar disorder without active airways disease, bronchospasm and possible symptoms of bronchospasm (which includes reports of wheezing, shortness of breath or cough) wereuncommon in patients treated with ADASUVE. However, in placebo-controlled clinical trials in subjects with mild-to-moderate persistent asthma or moderate-to-severe COPD, adverse reactions of bronchospasm were reported very commonly. Most of these events occurred within 25 minutes of dosing, were mild to moderate in severity, and could be relieved with an inhaled bronchodilator.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-09T01:00:00Z · SHA-256 bfb649bd10924d09174c1aad7b54613969e138520e897d565f22d8bf2ab6f147 · Passage 3e7481d8835b086129e0a3e70707b52eb9c062f9aa234ef2ed44b8bd2057cb8a · Zeichen 1768–2430 im Abschnitt